Clinical study of Wenyang Huoxue Lishui plaster in the treatment of chronic heart failure

Xiyuan Hospital, China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•(1) aged between 18 and 80 years old;
•(2) meet the diagnostic criteria for stable chronic heart failure;
•(3) New York Heart Association (NYHA) functional class II-III;
•(4) patients with reduced ejection fraction (LVEF < 40%);
•(5) The syndrome of Yang qi deficiency and blood stasis combined with phlegm and drink;
•(6) Lee's heart failure score =6;
•(7) The subjects had fully informed consent to participate in this study voluntarily, and signed the informed consent form by themselves.

•(1) Heart failure due to kidney, liver and other important organ failure;
•(2) Patients with severe heart failure or grade IV heart function were not included in the study.
•(3) presence of various malignant tumors or suspicious malignant tumors;
•(4) history of thrombotic disease within 6 months;
•(5) patients with obvious liver and kidney diseases or ALT and AST higher than ULN 1.5 times, creatinine and urea nitrogen higher than ULN 1.5 times;
•(6) patients with severe mental disorders, hematopoietic system diseases and other major diseases;
•(7) women who are pregnant, lactating or have a positive pregnancy test, or have plans to give birth within a certain period of time;
•(8) patients with redness, swelling, ulceration or skin diseases;
•(9) have participated or are participating in other clinical investigators within the past three months;
•(10) suspected or definite allergy to study drugs;
•(11) Factors that increase mortality: Patients with cardiogenic shock, severe ventricular arrhythmia, complete atrioventricular block, obstructive cardiomyopathy, unpatched valvular disease, constrictive pericarditis, pericardial tamponade, pulmonary embolism, obvious infection, uncontrolled hypertension, acute myocarditis, acute coronary syndrome, and chronic heart failure requiring device therapy were excluded.

发起方